Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
stenoparib
product6 mentionslast seen Nov 2, 2026
An orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2 in Phase 2 clinical trials for advanced ovarian cancer and other cancer types.
Relationships 20
- Allarity Therapeutics, Inc.developsstenoparib99% confidence6 sources
- Eisai Co. Ltd.developsstenoparib99% confidence5 sources
- Allarity Therapeutics, Inc.acquiresstenoparib99% confidence4 sources
- stenoparibapplies tocolorectal cancer99% confidence2 sources
- stenoparibapplies tosmall cell lung cancer99% confidence2 sources
- stenoparibapplies tosmall cell lung cancer treatment99% confidence2 sources
- stenoparibapplies toadvanced ovarian cancer treatment99% confidence2 sources
- stenoparibapplies toovarian cancer treatment99% confidence2 sources
- stenoparibapplies toadvanced ovarian cancer99% confidence1 source
- stenoparibapplies toovarian cancer98% confidence1 source
- stenoparibconforms toU.S. Food and Drug Administration97% confidence1 source
- Allarity Therapeutics, Inc.commercializesstenoparib97% confidence1 source
- stenoparibapplies torelapsed small cell lung cancer treatment90% confidence1 source
- stenoparibapplies toplatinum-resistant ovarian cancer treatment90% confidence1 source
- stenoparibdepends onPARP inhibition90% confidence1 source
- stenoparibdepends onWNT pathway inhibition90% confidence1 source
- stenoparibapplies tocancer treatment90% confidence1 source
- Drug Response Predictorcomposed ofstenoparib85% confidence1 source
- stenoparibcomposed ofstenoparib-DRP85% confidence1 source
- stenoparibapplies tocolorectal cancer treatment75% confidence1 source
Relationship
stenoparibapplies toovarian cancer treatment
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 6, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Allarity has advanced its Phase 2 ovarian cancer program
- filingSEC EDGARSep 29, 2026Allarity Therapeutics, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
developing stenoparib, a novel PARP/tankyrase inhibitor for patients with advanced ovarian cancer